Trial reportBioMed research international2014
Beneficial effects of testosterone therapy on functional capacity, cardiovascular parameters, and quality of life in patients with congestive heart failure.
Trial report in BioMed research international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 4 syntheses or guidelines pooled it, 58 citations in OpenAlex.
- Testosterone replacement therapy in heart failure: A systematic review of randomized controlled trials.Hormones (Athens, Greece) · 2025Pooled it
- Adult- and late-onset male hypogonadism: the clinical practice guidelines of the Italian Society of Andrology and Sexual Medicine (SIAMS) and the Italian Society of Endocrinology (SIE).Journal of endocrinological investigation · 2022Guideline
- Testosterone Supplementation in Patients With Chronic Heart Failure: A Meta-Analysis of Randomized Controlled Trials.Frontiers in endocrinology · 2020Pooled it
- Association of Testosterone Treatment With Alleviation of Depressive Symptoms in Men: A Systematic Review and Meta-analysis.JAMA psychiatry · 2019Pooled it
- Adjuvant testosterone therapy in chronic heart failure (ATTIC): a randomised open-label trial.BMJ open · 2022Trial
- Cardiovascular Disease and Androgens: Clinical Trends, Potential Mechanisms, and Considerations for Engineering Solutions.Cardiovascular engineering and technology · 2026Review
- Secondary Hypogonadism and Effects of Testosterone Replacement Therapy on Cardiovascular Events.The Journal of clinical endocrinology and metabolism · 2026Article
- Anabolic-Androgenic Steroids Revisited: Structural Biology, Receptor Signaling, and Mechanisms of Anabolic-Androgenic Dissociation.International journal of molecular sciences · 2026Review
- Review
- Testosterone therapy in patients with heart failure and protein-calorie malnutrition: Insights from a propensity-matched cohort study.Current problems in cardiology · 2025Review
- Molecular mechanisms underlying sarcopenia in heart failure.The journal of cardiovascular aging · 2024Article
- Testosterone deficiency impairs cardiac interfibrillar mitochondrial function and myocardial contractility while inducing oxidative stress.Frontiers in endocrinology · 2023Article
- Androgen-Regulated Cardiac Metabolism in Aging Men.Frontiers in endocrinology · 2020Review
- Systemic effects of the hormonal treatment of male hypogonadism with preliminary indications for the management of COVID-19 patients.Therapeutic advances in endocrinology and metabolism · 2020Review
- Testosterone, myocardial function, and mortality.Heart failure reviews · 2018Review
- Myopenia and precision (P4) medicine.Journal of cachexia, sarcopenia and muscle · 2017Article
- Sex differences in the regulation of spatially distinct cardiac mitochondrial subpopulations.Molecular and cellular biochemistry · 2016Article
- Will testosterone replacement therapy become a new treatment of chronic heart failure? A review based on 8 clinical trials.Journal of thoracic disease · 2016Review
- Testosterone modulates cardiac contraction and calcium homeostasis: cellular and molecular mechanisms.Biology of sex differences · 2015Review
- Testosterone and quality of life in patients with dilated cardiomyopathy.Discoveries (Craiova, Romania)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAccording to the present evidences suggesting association between low testosterone level and prediction of reduced exercise capacity as well as poor clinical outcome in patients with heart failure, we sought to determine if testosterone therapy improves clinical and cardiovascular conditions as well as quality of life status in patients with stable chronic heart failure.
methodsA total of 50 male patients who suffered from congestive heart failure were recruited in a double-blind, placebo-controlled trial and randomized to receive an intramuscular (gluteal) long-acting androgen injection (1 mL of testosterone enanthate 250 mg/mL) once every four weeks for 12 weeks or receive intramuscular injections of saline (1 mL of 0.9% wt/vol NaCl) with the same protocol.
resultsThe changes in body weight, hemodynamic parameters, and left ventricular dimensional echocardiographic indices were all comparable between the two groups. Regarding changes in diastolic functional state and using Tei index, this parameter was significantly improved. Unlike the group received placebo, those who received testosterone had a significant increasing trend in 6-walk mean distance (6MWD) parameter within the study period (P = 0.019). The discrepancy in the trends of changes in 6MWD between study groups remained significant after adjusting baseline variables (mean square = 243.262, F index = 4.402, and P = 0.045).
conclusionOur study strengthens insights into the beneficial role of testosterone in improvement of functional capacity and quality of life in heart failure patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.